Profound Medical Corp. (PROF)
Stock Price:
$17.93 USD
0.22 (1.24%)
Updated Jul 9, 2020 12:35 PM EDT - Market open
Key Info
| Market Cap |
288.36M |
| Revenue (ttm) |
4.22M |
| Net Income (ttm) |
-15.41M |
| Shares Out |
16.08M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 9, 2020 |
| Last Price |
$17.93 |
| Previous Close |
$17.71 |
| Change ($) |
0.22 |
| Change (%) |
1.24% |
| Day's Open |
17.78 |
| Day's Range |
17.50 - 18.31 |
| Day's Volume |
23,452 |
| 52-Week Range |
11.06 - 18.42 |
More Stats
| Market Cap |
288.36M |
| Enterprise Value |
284.56M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
16.08M |
| Float |
13.83M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
-1.29 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
265,824 |
| Short Ratio |
4.73 |
| Short % of Float |
n/a |
| Beta |
2.03 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
68.34 |
| PB Ratio |
5.08 |
| Revenue |
4.22M |
| Operating Income |
-15.09M |
| Net Income |
-15.41M |
| Free Cash Flow |
-15.29M |
| Net Cash |
3.80M |
| Net Cash / Share |
0.24 |
| Gross Margin |
57.27% |
| Operating Margin |
-357.63% |
| Profit Margin |
-365.30% |
| FCF Margin |
-362.37% |
| ROA |
-23.13% |
| ROE |
-42.14% |
| ROIC |
-131.40% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (7)
| Buy |
6 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$19.08*
(6.41% upside)
Low
11.6
Current: 17.93
High
28.0
Target: 19.08
*Average 12-month USD price target from 7 stock analysts.
Financial Performance
Financial numbers in millions CAD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 5.53 | 2.60 | 4.90 | - |
| Revenue Growth | 112.41% | -46.94% | - | - |
| Gross Profit | 3.17 | 0.82 | 1.87 | - |
| Operating Income | -19.77 | -20.19 | -17.63 | -15.64 |
| Net Income | -20.19 | -20.76 | -18.82 | -16.33 |
| Shares Outstanding | 11.85 | 11.85 | - | - |
| Earnings Per Share | -1.82 | -2.07 | -0.31 | -0.39 |
| Operating Cash Flow | -20.03 | -18.29 | -15.57 | -14.50 |
| Capital Expenditures | - | - | -0.43 | -0.86 |
| Free Cash Flow | -20.03 | -18.29 | -16.00 | -15.37 |
| Cash & Equivalents | 19.22 | 30.69 | 11.10 | 0.00 |
| Total Debt | 14.25 | 11.96 | 5.15 | - |
| Net Cash / Debt | 4.97 | 18.73 | 5.96 | 0.00 |
| Assets | 39.04 | 46.55 | 27.88 | - |
| Liabilities | 20.38 | 19.92 | 13.74 | - |
| Book Value | 18.66 | 26.63 | 14.14 | - |
Numbers in millions CAD, except per-share numbers.
Company Details
| Full Name |
Profound Medical Corp. |
| Country |
Canada |
| Employees |
75 |
| CEO |
Arun S. Menawat |
Stock Information
| Ticker Symbol |
PROF |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NASDAQ: PROF |
Description
Profound Medical Corp. operates as a medical technology company develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.